by A recent study published in JAMA Oncology highlights the significance of testing for measurable residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing blood cell transplant therapy. The research underscores the importance of ensuring no cancer cells remain in the body before patients receive donor cells to restore their healthy blood supply.
The study reveals that patients in remission from high-risk blood Cancer who undergo this testing have better outcomes. This finding emphasizes the practicality of testing for MRD, a condition characterized by the presence of cancer cells despite successful chemotherapy treatment.
Christopher Hourigan, a professor at Virginia Tech’s Fralin Biomedical Research Institute and director of the institute’s new Cancer Research Center in Washington, D.C., explains that this testing is achievable using commercially available kits in major hospital labs. Previously, such testing required specialized centers with customized technology and high levels of expertise.
In a study involving 537 AML patients treated across the United States, researchers employed a method called targeted ultra-deep DNA sequencing to search for specific gene mutations related to cancer in the blood of patients who were in remission but awaiting bone marrow transplants. This testing approach proved effective in detecting residual cancer cells, providing valuable information for clinicians and improving patient outcomes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
